Are molecular markers better for assessing risk in oral potentially malignant disorders?

Oral potentially malignant disorders (OPMDs) are lesions in the mouth that can turn into oral cancer. Doctors usually judge risk by looking at tissue under a microscope, a method called histopathological grading. This approach has limits, so researchers are studying molecular markers (biological signs in cells or genes) to see if they can predict cancer risk more accurately. Current evidence suggests molecular markers are promising, but they are not yet ready to replace standard grading.

What the research says

Standard histopathological grading, like the WHO 2017 system, is the gold standard for diagnosing OPMDs, but it has limitations in predicting which lesions will become cancer ⁸. Molecular markers could help fill this gap. For example, a review notes that OPMD progression involves changes in genes, epigenetics, and inflammation, and that molecular markers may improve risk assessment beyond what morphology alone can offer ³. Another study found that hypermethylation of specific genes (FAM19A4 and miR124-2) increased from normal tissue to benign lesions, OPMDs, and cancers, suggesting it could help predict progression ⁶. However, evidence for many markers is still weak. A systematic review on immune checkpoints found that PD-L1 expression might help predict malignant transformation, but the evidence is fragmented and not ready for clinical use ². Similarly, a meta-analysis of transcriptomic changes identified immune and signaling shifts in high-grade dysplasia, but these findings are still early ⁴. Some studies combine molecular markers with other data. For instance, an AI model that included KRT13 and p53 protein levels along with patient and tissue features predicted cancer progression in oral leukoplakia better than histology alone ⁷. But not all tools are molecular: VELscope, a light-based device, has high sensitivity but low specificity (45%), meaning it often flags lesions that are not actually dangerous ⁵. Overall, molecular markers are promising, but they are not yet proven to be better than standard grading for routine use.

What to ask your doctor

• Are molecular marker tests available for my lesion, and would they change my treatment plan?
• What is the evidence that these markers predict cancer risk better than standard biopsy grading?
• Should I consider additional tests like methylation or immune marker analysis?
• How often should I be monitored if my lesion has high-risk features?
• What are the limitations of current risk assessment methods for OPMDs?